UArizona Researchers Develop Regenerative, Safe Therapeutic for Alzheimer ' s Disease

UArizona Researchers Develop Regenerative, Safe Therapeutic for Alzheimer's Disease Developed in the University of Arizona Health Sciences Center for Innovation in Brain Science, the therapy has been licensed to startup NeuTherapeutics Inc. Paul Tumarkin Today Tech Launch Arizona423A0576.JPG Roberta Diaz Brinton Photo courtesy of Tech Launch Arizona and NeuTherapeuticsHealthScience and TechnologyCommercializationCompassionExplorationMedicineTech Launch Arizona Media contact(s)Paul Tumarkin Tech Launch Arizonapault@tla.arizona.edu520-626-8770 Researcher contact(s)Roberta Diaz Brinton Director, UA Center for Innovation in Brain Sciencerbrinton@email.arizona.edu(520) 626-4621University of Arizona researchers have developed a new therapy for Alzheimer ' s disease designed to restore cognitive function in early-stage patients. The therapy is now proceeding through a Phase 2b clinical trial.Phase 2b trials involve rigorous testing for efficacy in groups of 100 to 300 patients.The team, led byRoberta Diaz Brinton, director of the UArizona Health SciencesCenter for Innovation in Brain Science and a member of theBIO5 Institute, found that the neurosteroid allopregnanolone, or allo, used to treat women with postpartum depression,promotes connectivity between neural networks required for cognitive function by generating new neurons and synapses in patients in the early stages of Alzheimer ' s disease.Working withTech Launch Arizona, the office that commercializes inv...
Source: The University of Arizona: Health - Category: Universities & Medical Training Authors: Source Type: research